Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
Thomsen
H S
HS
Morcos
S K
SK
Dawson
P
P
D002614:Chelating Agents / Q000009:adverse effects* / Q000378:metabolism; D003287:Contrast Media / Q000009:adverse effects* / Q000378:metabolism; D005355:Fibrosis; D005682:Gadolinium / Q000378:metabolism; D019786:Gadolinium DTPA / Q000009:adverse effects* / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D007676:Kidney Failure, Chronic / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D006435:Renal Dialysis
D002614:Chelating Agents; D003287:Contrast Media; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA